Skip to content
MedsAcross

Medicine

Zithromax 250 mg tablet

Azithromycin · Oral · Pfizer Laboratories
Available on requestPrescription onlyUS FDA

Zithromax 250 mg tablet is a prescription medicine containing Azithromycin for oral use, marketed by Pfizer Laboratories, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

Store dry powder below 30°C (86°F). Store constituted suspension between 5° to…

Key facts

Active ingredient (INN)
Azithromycin
Brand
Zithromax
Strength
250 mg
Dosage form
Tablet
Route
Oral
Packs
3 blister pack, 30 tablets, 4 tablets and 1 more
Marketing authorisation holder
Pfizer Laboratories
Manufacturers
Pfizer LaboratoriesRedpharm Drug
Origin register
US FDA, United States
Storage
Store dry powder below 30°C (86°F). Store constituted suspension between 5° to 30°C (41° to 86°F) and discard when full dosing is completed.
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
ATC code
J01FA10 Azithromycin
HS code (indicative)
3004.20Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
18 July 1996
Identifiers
RxCUI 212446, 308460, 105260 +7DailyMed set ID 3ddecd25-dc32-a2af-e063-6294a90a526d, db52b91e-79f7-4cc1-9564-f2eee8e31c45NDC 67296-0020, 0069-3060, 0069-4061Application NDA050711

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
3 blister pack in 1 box / 6 tablet, film coated in 1 blister pack0069-3060-75Pfizer Laboratories18 July 1996
30 tablet, film coated in 1 bottle0069-4061-01Pfizer Laboratories4 May 2020
4 tablet, film coated in 1 bottle67296-0020-1Redpharm Drug18 July 1996
6 tablet, film coated in 1 bottle67296-0020-2Redpharm Drug18 July 1996

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 1 November 1991Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Azithromycin 250 mg tablet.

Compare 1

Other strengths and forms of Azithromycin

Clinical summary

Azithromycin is a macrolide antimicrobial indicated for treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below, among other approved uses. MedsAcross supplies Azithromycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Azithromycin

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Zithromax 250 mg tablet for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.